BusinessActinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-ABy Nasdaq OMXDec 13, 2016, 12:00 PM UTC
BusinessActinium to Sponsor Upcoming Blood & Marrow Transplant Information Network Webinar Focused on Stem Cell Transplants for Patients with AMLBy Nasdaq OMXDec 12, 2016, 12:00 PM UTC
BusinessActinium Highlights Results from Phase 1 Clinical Trial of Actimab-A at 58th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 6, 2016, 2:00 AM UTC
BusinessActinium Further Strengthens Clinical Development Team with Senior Hire to Support Later-Stage Clinical TrialsBy Nasdaq OMXNov 29, 2016, 12:00 PM UTC
BusinessActinium Issues Letter to Shareholders Highlighting 2016 Accomplishments and Anticipated Milestones for 2017By Nasdaq OMXNov 22, 2016, 12:00 PM UTC
BusinessActinium Pharmaceuticals to Present at LD Micro Main Event Investor ConferenceBy Nasdaq OMXNov 21, 2016, 12:00 PM UTC
BusinessActinium Announces Notice of Allowance for U.S. Patent Related to Actimab-ABy Nasdaq OMXNov 14, 2016, 12:00 PM UTC
BusinessINC Research Selected to Manage The Leukemia & Lymphoma Society’s First-ever Master Trial to Advance New Targeted Therapies for Acute Myeloid LeukemiaBy Nasdaq OMXNov 7, 2016, 4:15 PM UTC
